Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Bayer

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Bayer: Federal Court Brings an End to Roundup™ Litigation in Australia

January 03, 2025

From Bayer

Via Business Wire

Bayer Partners with America’s Grow-A-Row to Aid in the Fight Against Hunger in New Jersey

December 17, 2024

From Bayer

Via Business Wire

Bayer Showcases Growing Radiology Portfolio at RSNA 2024

December 01, 2024

From Bayer

Via Business Wire

Bayer Announces ‘Project Enhanced S3’ to Enable Companies to Realize Additional Sustainability Value from Carbon Removal Projects

November 21, 2024

From Bayer

Via Business Wire

U.S. FDA Accepts Supplemental New Drug Application for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer

November 21, 2024

From Bayer

Via Business Wire

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF ≥40% at AHA 2024

November 14, 2024

From Bayer

Via Business Wire

Bayer’s Receives FDA Clearance for MEDRAD® Centargo CT Injection System

November 07, 2024

From Bayer

Via Business Wire

Bayer and Liveo Research Launch First-of-its-Kind Blister Packaging with Improved Environmental Footprint

October 30, 2024

From Bayer

Via Business Wire

U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant

October 09, 2024

From Bayer

Via Business Wire

Bayer and MOMA Therapeutics Enter Collaboration and License Agreement in Oncology

October 08, 2024

From Bayer

Via Business Wire

BlueRock Therapeutics’ Investigational Cell Therapy Bemdaneprocel for Parkinson’s Disease Shows Positive Data at 24-Months

September 27, 2024

From Bayer

Via Business Wire

Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer

September 26, 2024

From Bayer

Via Business Wire

New Publication Evaluates Awareness of High Breast Density as a Risk Factor for Breast Cancer

September 25, 2024

From Bayer

Via Business Wire

Bayer, UPMC Magee-Women’s Hospital, PA Senate President Pro Tempore Kim Ward Collaborate to Bring Breast Health Care and Awareness to Pittsburgh Region’s Rural and Underserved Communities

September 24, 2024

From Bayer

Via Business Wire

ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA® (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer

September 16, 2024

From Bayer

Via Business Wire

Bayer Consumer Health Welcomes Bayer 04 Leverkusen to Kick Off Historic Trophy Tour in the U.S. After Undefeated Bundesliga Season

September 12, 2024

From Bayer

Via Business Wire

Welcome to “Wita”: Claritin® Aims to Take the ‘Itch’ Out of Wichita, the #1 Allergy Capital in the U.S., Just in Time for Fall Allergy Season

September 10, 2024

From Bayer

Via Business Wire

Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause

September 10, 2024

From Bayer

Via Business Wire

New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC

September 09, 2024

From Bayer

Via Business Wire

Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Research at ESMO 2024

September 05, 2024

From Bayer

Via Business Wire

Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated With Menopause

September 04, 2024

From Bayer

Via Business Wire

ESC 2024: Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

September 01, 2024

From Bayer

Via Business Wire

ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data

August 29, 2024

From Bayer

Via Business Wire

Bayer starts Phase III Trial in Non-Small Cell Lung Cancer (NSCLC)

August 29, 2024

From Bayer

Via Business Wire

Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology

August 28, 2024

From Bayer

Via Business Wire

Fast, Stable, Secure: New Bayer Hardware Simplifies Farm Activities, Equipment Setup and Provides Increased Value to Farmers

August 26, 2024

From Bayer

Via Business Wire

The Journal of American Medical Association (JAMA) publishes Elinzanetant Phase III data

August 22, 2024

From Bayer

Via Business Wire

Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With Chronic Kidney Disease

August 22, 2024

From Bayer

Via Business Wire

Bayer and Alara Imaging Announce Collaboration

August 05, 2024

From Bayer

Via Business Wire

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA® (finerenone) in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

August 05, 2024

From Bayer

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.